The U.S. Food and Drug Administration announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN) on Thursday. The program is designed to coordinate agency action on conditions affecting the brain and nervous system.

The Neuroscience Advancement and Innovation Nexus will bring together expertise from the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Center for Devices and Radiological Health. Its inaugural initiative is the Alzheimer's Prevention Accelerator, which will focus on advancing medical products that help delay or prevent Alzheimer's disease. The initiative will explore innovative approaches to clinical trials for Alzheimer’s prevention, emphasizing trial populations and stage-appropriate endpoints.

"The launch of NAIN reflects FDA's commitment — in support of the Trump Administration’s drive to transform health care innovation — to making sure our regulatory science and cross-center collaboration keep pace with the rapid advances happening in neuroscience," Acting FDA Commissioner Kyle Diamantas said.

The agency said the Neuroscience Advancement and Innovation Nexus is aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments. The FDA said the Neuroscience Advancement and Innovation Nexus and the Alzheimer's Prevention Accelerator support the National Alzheimer’s Project Act. The agency described the National Alzheimer’s Project Act as the federal government's comprehensive roadmap for coordinated action on Alzheimer's and related dementias.